Silverfin false false 31/03/2026 01/04/2025 31/03/2026 Dr Gavin Peter Ross Clunie 26/05/2023 03 October 2026 no description of principal activity 14897629 2026-03-31 14897629 bus:Director1 2026-03-31 14897629 2025-03-31 14897629 core:CurrentFinancialInstruments 2026-03-31 14897629 core:CurrentFinancialInstruments 2025-03-31 14897629 core:ShareCapital 2026-03-31 14897629 core:ShareCapital 2025-03-31 14897629 core:RetainedEarningsAccumulatedLosses 2026-03-31 14897629 core:RetainedEarningsAccumulatedLosses 2025-03-31 14897629 core:OfficeEquipment 2025-03-31 14897629 core:ComputerEquipment 2025-03-31 14897629 core:OfficeEquipment 2026-03-31 14897629 core:ComputerEquipment 2026-03-31 14897629 2025-04-01 2026-03-31 14897629 bus:FilletedAccounts 2025-04-01 2026-03-31 14897629 bus:SmallEntities 2025-04-01 2026-03-31 14897629 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 14897629 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 14897629 bus:Director1 2025-04-01 2026-03-31 14897629 core:OfficeEquipment core:TopRangeValue 2025-04-01 2026-03-31 14897629 core:ComputerEquipment core:TopRangeValue 2025-04-01 2026-03-31 14897629 2024-06-01 2025-03-31 14897629 core:OfficeEquipment 2025-04-01 2026-03-31 14897629 core:ComputerEquipment 2025-04-01 2026-03-31 iso4217:GBP xbrli:pure

Company No: 14897629 (England and Wales)

CLUNIE MEDICAL LIMITED

Unaudited Financial Statements
For the financial year ended 31 March 2026
Pages for filing with the registrar

CLUNIE MEDICAL LIMITED

Unaudited Financial Statements

For the financial year ended 31 March 2026

Contents

CLUNIE MEDICAL LIMITED

STATEMENT OF FINANCIAL POSITION

As at 31 March 2026
CLUNIE MEDICAL LIMITED

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 March 2026
Note 31.03.2026 31.03.2025
£ £
Fixed assets
Tangible assets 3 448 921
448 921
Current assets
Debtors 4 6,774 1,413
Cash at bank and in hand 177,315 116,766
184,089 118,179
Creditors: amounts falling due within one year 5 ( 26,017) ( 9,902)
Net current assets 158,072 108,277
Total assets less current liabilities 158,520 109,198
Net assets 158,520 109,198
Capital and reserves
Called-up share capital 1 1
Profit and loss account 158,519 109,197
Total shareholder's funds 158,520 109,198

For the financial year ending 31 March 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of Clunie Medical Limited (registered number: 14897629) were approved and authorised for issue by the Director. They were signed on its behalf by:

Dr Gavin Peter Ross Clunie
Director

03 October 2026

CLUNIE MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2026
CLUNIE MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2026
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial period, unless otherwise stated.

General information and basis of accounting

Clunie Medical Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 1 The Atrium Phoenix Square, Wyncolls Road, Colchester, CO4 9AS, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the supply of services represents the value of services provided under contracts to the extent that there is a right to consideration and is recorded at the fair value of the consideration received or receivable. Where a contract has only been partially completed at the reporting date turnover represents the fair value of the service provided to date based on the stage of completion of the contract activity at the reporting date. Where payments are received from customers in advance of services provided, the amounts are recorded as deferred income and included as part of creditors due within one year.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Office equipment 3 years straight line
Computer equipment 3 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in the Income Statement as described below.

2. Employees

Year ended
31.03.2026
Period from
01.06.2024 to
31.03.2025
Number Number
Monthly average number of persons employed by the Company during the year, including the director 1 1

3. Tangible assets

Office equipment Computer equipment Total
£ £ £
Cost
At 01 April 2025 475 946 1,421
At 31 March 2026 475 946 1,421
Accumulated depreciation
At 01 April 2025 211 289 500
Charge for the financial year 158 315 473
At 31 March 2026 369 604 973
Net book value
At 31 March 2026 106 342 448
At 31 March 2025 264 657 921

4. Debtors

31.03.2026 31.03.2025
£ £
Trade debtors 6,774 1,413

5. Creditors: amounts falling due within one year

31.03.2026 31.03.2025
£ £
Amounts owed to director 3,578 709
Accruals 1,980 1,890
Taxation and social security 20,459 7,303
26,017 9,902

6. Related party transactions

Transactions with the entity's director

31.03.2026 31.03.2025
£ £
Amounts owed to director 3,578 709